Folgen
Xiaopei Shen
Xiaopei Shen
Fujian Medical University
Bestätigte E-Mail-Adresse bei fjmu.edu.cn
Titel
Zitiert von
Zitiert von
Jahr
Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants
X Shi, R Liu, F Basolo, R Giannini, X Shen, D Teng, H Guan, Z Shan, ...
The Journal of Clinical Endocrinology & Metabolism 101 (1), 264-274, 2016
2032016
Separate enrichment analysis of pathways for up-and downregulated genes
G Hong, W Zhang, H Li, X Shen, Z Guo
Journal of the Royal Society Interface 11 (92), 20130950, 2014
1352014
Patient Age–Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer
X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, L Fugazzola, ...
Journal of Clinical Oncology 36 (5), 438-445, 2018
802018
The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer
F Wang, X Yu, X Shen, G Zhu, Y Huang, R Liu, D Viola, R Elisei, ...
The Journal of Clinical Endocrinology & Metabolism 102 (9), 3241–3250, 2017
792017
BRAF V600E mutation-assisted risk stratification of solitary intrathyroidal papillary thyroid cancer for precision treatment
Y Huang, S Qu, G Zhu, F Wang, R Liu, X Shen, D Viola, R Elisei, ...
JNCI: Journal of the National Cancer Institute 110 (4), 362-370, 2018
652018
A six-genotype genetic prognostic model for papillary thyroid cancer
X Shen, R Liu, M Xing
Endocrine-related cancer, ERC-16-0402, 2017
612017
REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer
D Liu, X Shen, G Zhu, M Xing
Oncotarget 6 (36), 39211, 2015
542015
Response.
T Zhang, X Shen, M Xing
Journal of the National Cancer Institute 108 (8), 2016
51*2016
The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer
J Liu, R Liu, X Shen, G Zhu, B Li, M Xing
Journal of Nuclear Medicine 61 (2), 177-182, 2020
502020
BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer
F Wang, S Zhao, X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, ...
Journal of clinical oncology 36 (27), 2787, 2018
452018
BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma
KJ Kim, SG Kim, J Tan, X Shen, D Viola, R Elisei, E Puxeddu, L Fugazzola, ...
European Journal of Cancer 124, 161-169, 2020
322020
Distinct functional patterns of gene promoter hypomethylation and hypermethylation in cancer genomes
X Shen, Z He, H Li, C Yao, Y Zhang, L He, S Li, J Huang, Z Guo
Public Library of Science 7 (9), e44822, 2012
262012
Reproducibility and concordance of differential DNA methylation and gene expression in cancer
C Yao, H Li, X Shen, Z He, L He, Z Guo
PLoS One 7 (1), e29686, 2012
252012
An integrated approach to uncover driver genes in breast cancer methylation genomes
X Shen, S Li, L Zhang, H Li, G Hong, XX Zhou, T Zheng, W Zhang, C Hao, ...
PLoS One 8 (4), e61214, 2013
172013
BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer
Y Tao, F Wang, X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, ...
The Journal of Clinical Endocrinology & Metabolism 106 (11), 3228-3238, 2021
142021
Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer
L Zhang, C Hao, X Shen, G Hong, H Li, X Zhou, CY Liu, Z Guo
Breast cancer research and treatment 139 (2), 361-369, 2013
132013
Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness
T Zhang, X Shen, R Liu, G Zhu, J Bishop, M Xing
Oncotarget 8 (1), 900, 2017
122017
Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2
R Liu, J Tan, X Shen, K Jiang, C Wang, G Zhu, M Xing
Proceedings of the National Academy of Sciences 118 (11), 2021
92021
Finding co-mutated genes and candidate cancer genes in cancer genomes by stratified false discovery rate control
J Wang, Y Zhang, X Shen, J Zhu, L Zhang, J Zou, Z Guo
Molecular BioSystems 7 (4), 1158-1166, 2011
92011
Genes dysregulated to different extent or oppositely in estrogen receptor-positive and estrogen receptor-negative breast cancers
X Zhou, T Shi, B Li, Y Zhang, X Shen, H Li, G Hong, C Liu, Z Guo
PLoS One 8 (7), e70017, 2013
82013
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20